Chengdu, China, September 9, 2021 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today its first granted US patent (11104633), entitled “cancer treatment using compounds that selectively target polyploid cancer cells for disruption”, which was issued by the US Patent and Trademark Office (USPTO) on August 31.

The method covered in this patent has been used to identify compounds that selectively kill polyploid cells, key to the discovery of inhibitors of MYC, overexpression of which occurs in over half of tumors and is correlated with poorly differentiated and aggressive cancer.  

Dun Yang PhD, Founder, President, and CEO of ACB, said: “The grant of our first patent in the USA is a key milestone and underlines our innovative approach to identifying first-in-class and best-in-class approaches for the treatment of cancer, using synthetic lethal approaches. It forms part of our growing patent estate with nine additional patents pending, covering both methods and composition of matter.”

ACB is applying synthetic lethal approaches to develop targeted cancer therapies. These have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.

With five drug discovery programs, ACB is progressing rapidly through optimization to candidate selection toward IND enabling studies, with the aim of initiating two clinical trials in the USA in 2022.